The mol­e­cules known as triple-Gs — ag­o­nists of GLP-1, GIP and glucagon — are draw­ing at­ten­tion as da­ta build sug­gest­ing they could be the most...

Bill Meury has been in or led the C-suite of sev­er­al bio­phar­ma com­pa­nies that have con­struct­ed multi­bil­lion-dol­lar ex­its over the past decade: Al­ler­gan, Karuna and...

City Ther­a­peu­tics, the next-gen RNAi start­up found­ed and led by for­mer Al­ny­lam ex­ec­u­tives, has col­lect­ed $99.5 mil­lion to fund the clin­i­cal de­vel­op­ment of its first...

Take­da has up­dat­ed its fi­nan­cial re­sults to re­flect costs it could in­cur af­ter los­ing an an­titrust law­suit con­cern­ing its lax­a­tive drug Ami­ti­za.

In May, the...

Boehringer In­gel­heim’s obe­si­ty as­set sur­vo­du­tide, which it li­censed from Zealand Phar­ma, has shown high rates of dis­con­tin­u­a­tions in its Phase 3 obe­si­ty study.

In April...